Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)

Trial Profile

Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2016

At a glance

  • Drugs PEG loxenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Jiangsu Hansoh Pharmaceutical
  • Most Recent Events

    • 25 Jan 2016 Planned end date changed from 1 Dec 2015 to 1 May 2016, as reported by ClinicalTrials.gov.
    • 25 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
    • 15 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top